

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: HIL1/22 - Serum Indices

Deadline: 22.04.2022

| | | |
|--|--|--|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of the participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | U _{AV} = expanded uncertainty of the assigned value (k = 2) | |

| Test | [unit] | | | | | | Comparability | | | | | | | |
|---|----------|------|------|--------|------------------|------------------|----------------------|-----------------|------------------|------|------|------------------|------------------|------------------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} |
| (501) Hemolytic index (quantitative) | | | | | 71 | | | | | | | 71 | 57 | 80% |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | |
| Sample A | | 28,0 | 6,9 | 24 | 71 | CVP | 28 | 2,1 | 60% | 11,2 | 44,8 | 71 | 58 | 82% |
| (1) Abbott | | 25,9 | 2,2 | 8,4 | 22 | | | | | | | 22 | | |
| (60) Roche | | 28,6 | 7,8 | 27 | 43 | | | | | | | 43 | | |
| Other | | | | | 6 | | | | | | | 6 | | |
| | | | | | | | 1x 12, 2x 58, 3x 162 | | | | | | | |
| Sample B | | 79,0 | 7,2 | 9,1 | 71 | CVP | 79 | 2,2 | 23% | 60,8 | 97,2 | 71 | 62 | 87% |
| (1) Abbott | | 77,5 | 2,8 | 3,6 | 22 | | | | | | | 22 | | |
| (60) Roche | | 78,1 | 8,8 | 11 | 43 | | | | | | | 43 | | |
| Other | | | | | 6 | | | | | | | 6 | | |
| | | | | | | | 1x 12, 2x 58, 3x 162 | | | | | | | |
| (502) Icteric index (quantitative) | | | | | 71 | | | | | | | 71 | 69 | 97% |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | |
| Sample A | | 463 | 36 | 7,7 | 71 | CVP | 463 | 10 | 20% | 370 | 556 | 71 | 69 | 97% |
| (1) Abbott | | 468 | 34 | 7,2 | 22 | | | | | | | 22 | | |
| (60) Roche | | 461 | 34 | 7,3 | 43 | | | | | | | 43 | | |
| Other | | | | | 6 | | | | | | | 6 | | |
| | | | | | | | 1x 12, 2x 58, 3x 162 | | | | | | | |
| Sample B | | 242 | 33 | 14 | 71 | CVP | 242 | 9,7 | 35% | 157 | 327 | 71 | 69 | 97% |
| (1) Abbott | | 208 | 21 | 10 | 22 | | | | | | | 22 | | |
| (60) Roche | | 257 | 18 | 6,8 | 43 | | | | | | | 43 | | |
| Other | | | | | 6 | | | | | | | 6 | | |
| | | | | | | | 1x 12, 2x 58, 3x 162 | | | | | | | |
| (503) Lipemic index (quantitative) | | | | | 68 | | | | | | | 68 | 65 | 96% |
| Samples and groups | [g/L] | | | | | | | | | | | | | |
| Sample A | | 4,93 | 0,58 | 12 | 68 | CVP | 4,93 | 0,17 | 30% | 3,45 | 6,41 | 68 | 66 | 97% |
| (1) Abbott | | 4,34 | 0,35 | 8,1 | 19 | | | | | | | 19 | | |
| (60) Roche | | 5,25 | 0,27 | 5,1 | 43 | | | | | | | 43 | | |
| Other | | | | | 6 | | | | | | | 6 | | |
| | | | | | | | 1x 12, 2x 58, 3x 162 | | | | | | | |
| Sample B | | 4,01 | 0,42 | 10 | 68 | CVP | 4,01 | 0,12 | 25% | 3 | 5,02 | 68 | 66 | 97% |
| (1) Abbott | | 3,58 | 0,31 | 8,6 | 19 | | | | | | | 19 | | |
| (60) Roche | | 4,19 | 0,27 | 6,4 | 43 | | | | | | | 43 | | |
| Other | | | | | 6 | | | | | | | 6 | | |
| | | | | | | | 1x 12, 2x 58, 3x 162 | | | | | | | |

st_kn_p

End of report

Printed: 05.05.2022